Decheng Capital Global Life Sciences Fund Iv, L.p. - Net Worth and Insider Trading
Decheng Capital Global Life Sciences Fund Iv, L.p. Net Worth
The estimated net worth of Decheng Capital Global Life Sciences Fund Iv, L.p. is at least $194 Million dollars as of 2024-09-20. Decheng Capital Global Life Sciences Fund Iv, L.p. is the 10% Owner of CG Oncology Inc and owns about 4,958,812 shares of CG Oncology Inc (CGON) stock worth over $194 Million. Details can be seen in Decheng Capital Global Life Sciences Fund Iv, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Decheng Capital Global Life Sciences Fund Iv, L.p. has not made any transactions after 2024-01-29 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Decheng Capital Global Life Sciences Fund Iv, L.p.
Decheng Capital Global Life Sciences Fund Iv, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Decheng Capital Global Life Sciences Fund Iv, L.p. owns 1 companies in total, including Equillium Inc (EQ) .
Insider Ownership Summary of Decheng Capital Global Life Sciences Fund Iv, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| EQ | Equillium Inc | 2021-02-05 | 10 percent owner |
Decheng Capital Global Life Sciences Fund Iv, L.p. Latest Holdings Summary
Decheng Capital Global Life Sciences Fund Iv, L.p. currently owns a total of 1 stock. Decheng Capital Global Life Sciences Fund Iv, L.p. owns 4,958,812 shares of CG Oncology Inc (CGON) as of January 29, 2024, with a value of $194 Million.
Latest Holdings of Decheng Capital Global Life Sciences Fund Iv, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CGON | CG Oncology Inc | 2024-01-29 | 4,958,812 | 39.11 | 193,939,137 |
Holding Weightings of Decheng Capital Global Life Sciences Fund Iv, L.p.
Decheng Capital Global Life Sciences Fund Iv, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Decheng Capital Global Life Sciences Fund Iv, L.p. has made a total of 2 transactions in CG Oncology Inc (CGON) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in CG Oncology Inc is the acquisition of 400,000 shares on January 29, 2024, which cost Decheng Capital Global Life Sciences Fund Iv, L.p. around $8 Million.
Insider Trading History of Decheng Capital Global Life Sciences Fund Iv, L.p.
- 1
Decheng Capital Global Life Sciences Fund Iv, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Decheng Capital Global Life Sciences Fund Iv, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Decheng Capital Global Life Sciences Fund Iv, L.p. is 17.08%. GuruFocus also compares Decheng Capital Global Life Sciences Fund Iv, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Decheng Capital Global Life Sciences Fund Iv, L.p. within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Decheng Capital Global Life Sciences Fund Iv, L.p.'s insider trading performs compared to the benchmark.
Performance of Decheng Capital Global Life Sciences Fund Iv, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 20.84 |  | | | | |
| Relative Return to S&P 500(%) | 17.42 | | | | | |
Decheng Capital Global Life Sciences Fund Iv, L.p. Ownership Network
Decheng Capital Global Life Sciences Fund Iv, L.p. Owned Company Details
What does Equillium Inc do?
Who are the key executives at Equillium Inc?
Decheng Capital Global Life Sciences Fund Iv, L.p. is the 10 percent owner of Equillium Inc. Other key executives at Equillium Inc include Chief Financial Officer Jason A Keyes , Sr. Vice President and COO Christine Zedelmayer , and director & Chief Scientific Officer Stephen Connelly .
Equillium Inc (EQ) Insider Trades Summary
Over the past 18 months, Decheng Capital Global Life Sciences Fund Iv, L.p. made no insider transaction in Equillium Inc (EQ). Other recent insider transactions involving Equillium Inc (EQ) include a net sale of 38,806 shares made by , and a net sale of 10,000 shares made by Jason A Keyes .
In summary, during the past 3 months, insiders sold 48,806 shares of Equillium Inc (EQ) in total and bought 0 shares, with a net sale of 48,806 shares. During the past 18 months, 48,806 shares of Equillium Inc (EQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 48,806 shares.
Equillium Inc (EQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Equillium Inc Insider Transactions
Decheng Capital Global Life Sciences Fund Iv, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Decheng Capital Global Life Sciences Fund Iv, L.p.. You might contact Decheng Capital Global Life Sciences Fund Iv, L.p. via mailing address: C/o Maples Corporate Services Limited, Ugland House, P.o. Box 309, Grand Cayman E9 Ky1-1104.
Discussions on Decheng Capital Global Life Sciences Fund Iv, L.p.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
